"PCure PCure Ltd. a leading provider of PatientCentric solutions for proton therapy has received U.S. Food and Drug Administration FDA approval for its patented upright imaging solution. The PCure system is based on a diagnosticquality computed tomography CT enabling treatment planning positioning and treatment delivery for cancer patients in a seated position.  The PCure PatientCentric solution is a paradigm shifting change from the current method of treatment with the patient in the horizontal position.  The benefits of treating patients in a seated position include greater patient comfort less internal organ movement better saliva drainage and a better position for breathing for asthmatic and other patients experiencing impaired breathing. It may also deliver less collateral radiation to sensitive organs while enabling greater accuracy in proton beam delivery said Michael Marash Ph.D. founder and CEO of PCure. Adult and pediatric patients who will initially benefit from this clinical breakthrough will be those treated for cancers of the lung breast chest the head and neck and lower torso. In addition to the clinical benefits of PCures solution there are also significant economic advantages to treating patients in a seated position. With PCure oncologists can develop a compact gantryless proton center for significantly less capital and operating costs essentially making proton therapy more widely available and attainable.  Because of the high capital costs proton therapy is currently only available to less than one percent of patients who could potentially benefit from it. The PCure gantryless system significantly reduces many factors associated with proton therapy including the capital cost of equipment and construction the size of a single room center or multiroom expandable center and the time from center planning to treatment.  We are excited to receive FDA clearance for our upright imaging technology. We are looking forward to demonstrating the clinical benefits of our PatientCentric approach for treatment planning immobilization adaptive therapy and motion management. The PCure team is committed to enabling all oncology centers and hospitals globally to establish costeffective proton therapy services for the best possible care and cure said Dr. Marash. About PCure PCure is the innovative provider of imageguided solutions for better clinical effectiveness of proton therapy at a fraction of the current capital and operating costs. PCure continues to develop advanced patientcentric solutions with a focus on adaptive therapy and real time motion management. PCures first product was cleared by the FDA in . http PCure works both with the existing and new cancer centers to establish advanced proton therapy capabilities."